Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 18:2022:4640788.
doi: 10.1155/2022/4640788. eCollection 2022.

Cardiorenal Disease in COVID-19 Patients

Muhtasham Sifaat  1 , Pinak Patel  1 , Razan Sheikh  1 , Dawood Ghaffar  1 , Hitesh Vaishnav  1 , Ludmila Nahar  2 , Sonia Rupani  3 , Syed Quadri  1
Affiliations
Review

Cardiorenal Disease in COVID-19 Patients

Muhtasham Sifaat et al. J Renin Angiotensin Aldosterone Syst. .

Abstract

Coronavirus disease 2019 (COVID-19) is an illness caused by a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Mutations in the genetic coding and the variations in the spike proteins are critical for the virus's mechanism of facilitating fusion with the human host, making the disease more severe. Recent research indicates that comorbidities including diabetes, hypertension, renal disease, heart failure, and atherosclerosis play a significant role in the severity and high mortality rates of (COVID-19), suggesting that perhaps the metabolic syndrome and its components are associated with COVID-19 morbidity. Primarily, angiotensin-converting enzyme 2 (ACE2) receptor is identified as the entrance receptor of SARS-CoV-2. Increased ACE2 expression, endothelial dysfunction plays a vital role in the progression and severity of complications developed due to COVID-19. In this review, we will discuss the association and management of cardiorenal disease and COVID-19.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflicts of interest in this work.

References

    1. University JH. Coronavirus resource center COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) February 2022, https://coronavirus.jhu.edu/map.html.
    1. Wu Z., McGoogan J. M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA . 2020;323(13):1239–1242. doi: 10.1001/jama.2020.2648. - DOI - PubMed
    1. Powell J., Piszczatoski C. R. Finally, an FDA approval for an immunization against COVID-19: hope on the horizon. Annals of Pharmacotherapy . 2022;10:p. 10600280211058387. doi: 10.1177/10600280211058387. - DOI - PubMed
    1. Vasireddy D., Atluri P., Malayala S. V., Vanaparthy R., Mohan G. Review of COVID-19 vaccines approved in the United States of America for emergency use. Journal of Clinical Medical Research . 2021;13(4):204–213. doi: 10.14740/jocmr4490. - DOI - PMC - PubMed
    1. Bosch B. J., van der Zee R., de Haan C. A., Rottier P. J. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. Journal of Virology . 2003;77(16):8801–8811. doi: 10.1128/JVI.77.16.8801-8811.2003. - DOI - PMC - PubMed

Substances